Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2

[1]  D. Salomon,et al.  A betacellulin mutant promotes differentiation of pancreatic acinar AR42J cells into insulin-producing cells with low affinity of binding to ErbB1. , 2008, Journal of molecular biology.

[2]  Mads Lerdrup,et al.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. , 2007, Molecular biology of the cell.

[3]  B. van Deurs,et al.  Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way , 2006, Journal of Cell Science.

[4]  L. E. Johannessen,et al.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. , 2005, Molecular biology of the cell.

[5]  M. Seno,et al.  Identification of cell surface marker candidates on SV-T2 cells using DNA microarray on DLC-coated glass. , 2005, Biochemical and biophysical research communications.

[6]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[8]  D. Weaver,et al.  Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells , 2004, International journal of cancer.

[9]  B. van Deurs,et al.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. , 2004, Molecular biology of the cell.

[10]  D. Lauffenburger,et al.  Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis , 2003, Journal of Biological Chemistry.

[11]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[12]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[13]  Vladislav V Glinsky,et al.  Identification and Characterization of Peptides That Bind Human ErbB-2 Selected from a Bacteriophage Display Library , 2002, Journal of protein chemistry.

[14]  P. Monaci,et al.  Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. , 2001, Journal of molecular biology.

[15]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[16]  J. Baselga,et al.  Mechanism of action of trastuzumab and scientific update. , 2001, Seminars in oncology.

[17]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[18]  P. Dennis,et al.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. , 2001, Cancer research.

[19]  P. Schneider,et al.  Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB‐2 receptor , 2001, International journal of cancer.

[20]  D. Birnbaum,et al.  The ERBB2/HER2 Receptor Differentially Interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 Domain Proteins* , 2001, The Journal of Biological Chemistry.

[21]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[22]  G. Carpenter,et al.  Geldanamycin Induces ErbB-2 Degradation by Proteolytic Fragmentation* , 2000, The Journal of Biological Chemistry.

[23]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[24]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[25]  D. Birnbaum,et al.  ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor , 2000, Nature Cell Biology.

[26]  T. K. Yeung,et al.  Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. , 1999, Molecular biology of the cell.

[27]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[28]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[29]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[30]  J. McCafferty,et al.  Antibody engineering: a practical approach , 1997 .

[31]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[32]  M. Sliwkowski,et al.  Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. , 1996, Cancer research.

[33]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[34]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[35]  Y. Yarden,et al.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Carpenter,et al.  The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.

[37]  C. Waters,et al.  Endocytosis of growth factor receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  R. Bast,et al.  Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. , 1991, Cancer research.

[39]  M. Kraus,et al.  Oncogenic potential of erbB-2 in human mammary epithelial cells. , 1991, Oncogene.

[40]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[41]  T. Watanabe,et al.  Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. , 1990, Molecular endocrinology.

[42]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[43]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[44]  M. Hung,et al.  Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. , 1989, Oncogene.